1. Home
  2. ANIX vs ASMB Comparison

ANIX vs ASMB Comparison

Compare ANIX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.59

Market Cap

135.3M

Sector

Health Care

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$36.12

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
ASMB
Founded
1982
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.3M
553.6M
IPO Year
1987
2010

Fundamental Metrics

Financial Performance
Metric
ANIX
ASMB
Price
$3.59
$36.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$9.00
$43.40
AVG Volume (30 Days)
353.5K
131.0K
Earning Date
01-09-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$37,191,000.00
Revenue This Year
N/A
$42.01
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.30
52 Week Low
$2.07
$7.75
52 Week High
$5.46
$39.71

Technical Indicators

Market Signals
Indicator
ANIX
ASMB
Relative Strength Index (RSI) 36.66 57.82
Support Level $4.20 $35.05
Resistance Level $5.46 $38.82
Average True Range (ATR) 0.42 1.91
MACD -0.06 -0.32
Stochastic Oscillator 3.40 42.70

Price Performance

Historical Comparison
ANIX
ASMB

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: